Roy Herbst, MD, PhD, Yale Cancer Center

home / authors / roy-herbst-md-phd-yale-cancer-center

Articles

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 25th 2021

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Perioperative Approaches to NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

August 25th 2021

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Biomarkers for Immunotherapy in Resectable NSCLC

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Neal Edward Ready, MD, PhD, Duke Medical Center;Sandip P. Patel, MD, University of California San Diego

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.